December 6th 2024
Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
November 23rd 2024
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
November 22nd 2024
Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.
Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition
Thermo Fisher will add Olink to its Life Sciences Solutions business.
Pfizer and Evotec Partner for Drug Discovery
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen
The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.
GSK and CureVac Enter into Licensing Agreement
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership
LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.
Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.
AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
Lantheus Acquires Rights to Life Molecular’s RM2 Targeting GRPR for Prostate and Breast Cancers
GRPR, or gastrin-releasing peptide receptor, is part of the bombesin G protein-coupled receptor family and has been found to be overexpressed in multiple cancers.
Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US
This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.
CDMOs Announce Strategic Partnership for Fully Integrated Manufacturing Solutions
The pairing of Abzena and Argonaut Manufacturing Services is the result of several years’ worth of collaborative work between the two companies.
Demand Remains Strong for Mammalian Cell Culture Capacity (BIO 2024)
Lars Petersen, CEO, FUJIFILM Diosynth Biotechnologies discusses the company’s strategic goals and meeting market demand for mammalian cell culture capacity.
Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion
With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.
Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
IMA Life North America Breaks Ground on New Facility in Tonawanda, NY
The new 80,000-square-foot facility will increase production of the company’s freeze-drying equipment.
Frontrunners in CNS Drug Delivery
Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.
New Cell Factory Box Launched by ProPharma and PBL for Automated CGT Manufacturing
ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.
Poseida Therapeutics and Astellas to Develop Novel Allogeneic Cell Therapies
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.
Improving Patient Access Through the UK IDAP Scheme
The IDAP pilot scheme is designed to accelerate access to innovative medical devices and is a pioneering legislative proposal in the UK medical device space.
Royal Recognition
Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.
N4 Pharma and SRI to Collaborate on Intracellular Delivery to Specific Target Cells
The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.
Charles River to Provide pDNA Manufacturing Services in Two Deals
Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.
Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy
Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.
Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio
Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.
AbbVie Gains Landos Biopharma and Full FDA Approval for ADC Product
The Landos acquisition adds a lead asset in autoimmune and inflammatory disease to AbbVie's portfolio, while the company's ADC, ELAHERE, gets full FDA approval.
AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion
AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.